AbCellera Biologics

The company was started by Carl Hansen, Véronique Lecault, Kevin Heyries, Daniel Da Costa, and Oleh Petriv in 2012. To date, the company has raised approximately $780 million, most recently through an IPO that raised $483 million in December 2020. Among its investors, we emphasize Data Collective, P...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Genevant enters partnership with Takeda for developing rare liver disease therapies

News Commentary | September 08, 2021

Genevant Sciences develops lipid nanoparticle (LNP) nucleic acid delivery techniques, which can be utilized for mRNA‑based applications including vaccines, protein production, and nonviral gene therapies. The two companies reached an agreement for Genevant to develop therapeutics for two undisclosed... Not part of subscription

Regulus Therapeutics

Company Profile | December 01, 2021

Regulus Therapeutics was created as a joint venture between Alnylam Pharmaceuticals, an RNAi therapeutics company, and Isis Pharmaceuticals (now known as Ionis Pharmaceuticals), a company focused on anti‑sense technologies and therapeutics, in 2007 Regulus Therapeutics is focused on the ... Not part of subscription

Pfizer partnering with Alex Therapeutics to develop nicotine-addiction DTx

News Commentary | February 08, 2022

Pfizer has partnered with Stockholm‑based DTx (digital therapeutics) maker Alex Therapeutics to deploy artificial intelligence (AI)‑based digital therapeutics. The Alex DTx platform combines cognitive‑based therapy and acceptance and commitment therapy with AI to offer personalized treatment plans. ... Not part of subscription